Needham Downgrades Clarus Therapeutics Hldgs to Hold

Needham analyst Serge Belanger downgrades Clarus Therapeutics Hldgs (NASDAQ:CRXT) from Buy to Hold.

Needham analyst Serge Belanger downgrades Clarus Therapeutics Hldgs (NASDAQ:CRXT) from Buy to Hold.

Total
0
Shares
Related Posts
Read More

Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pha…

Cantex to Expand Collaboration with Georgetown's Lombardi Comprehensive Cancer Center WESTON, Fla., June 1, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical

VTVT